» Articles » PMID: 23728143

Elimination of Hepatitis C Virus Infection Among People Who Inject Drugs Through Treatment As Prevention: Feasibility and Future Requirements

Overview
Journal Clin Infect Dis
Date 2013 Jun 4
PMID 23728143
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

The demonstration that antiretroviral treatment is effective for the prevention of human immunodeficiency virus (HIV) transmission has important implications for HCV prevention. HCV therapeutic development is advancing rapidly, with effective, simplified regimens available in the near future. In contrast to HIV, HCV treatment is both curative and circumscribed in duration-2 features that hold great promise for the potential effectiveness of HCV treatment as prevention, particularly among PWID. Mathematical modeling studies have suggested that modest increases in HCV treatment uptake could lead to substantial reductions in HCV prevalence. This Viewpoint focuses on issues that are important to consider when discussing the feasibility and future requirements of HCV treatment as prevention among PWID. This includes a need to address low rates of HCV screening and treatment, a limited HCV treatment infrastructure, the cost of therapy, and the balance of health priorities at the population and individual levels.

Citing Articles

Excitable models: Projections, targets, and the making of futures without disease.

Rhodes T, Lancaster K Sociol Health Illn. 2021; 43(4):859-880.

PMID: 33942914 PMC: 8360046. DOI: 10.1111/1467-9566.13263.


High HCV cure rates among people who inject drugs and have suboptimal adherence: A patient-centered approach to HCV models of care.

Norton B, Akiyama M, Arnsten J, Agyemang L, Heo M, Litwin A Int J Drug Policy. 2021; 93:103135.

PMID: 33667826 PMC: 8725059. DOI: 10.1016/j.drugpo.2021.103135.


Age and gender-specific hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington.

Corcorran M, Tsui J, Scott J, Dombrowski J, Glick S Drug Alcohol Depend. 2021; 220:108525.

PMID: 33461152 PMC: 7938869. DOI: 10.1016/j.drugalcdep.2021.108525.


Presenting a conceptual framework for an HIV prevention and care continuum and assessing the feasibility of empirical measurement in Estonia: A case study.

Uuskula A, Vickerman P, Raag M, Walker J, Paraskevis D, Eritsyan K PLoS One. 2020; 15(10):e0240224.

PMID: 33035238 PMC: 7546465. DOI: 10.1371/journal.pone.0240224.


Prevalence and high risk behaviours associated with HCV testing among people who inject drugs: a systematic review and Meta-analysis.

Karimi S, Bayani A, Higgs P, Bayat A, Hemmat M, Ahounbar E Subst Abuse Treat Prev Policy. 2020; 15(1):64.

PMID: 32831107 PMC: 7445934. DOI: 10.1186/s13011-020-00306-1.